BR112014010391A2 - composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica - Google Patents

composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica

Info

Publication number
BR112014010391A2
BR112014010391A2 BR112014010391A BR112014010391A BR112014010391A2 BR 112014010391 A2 BR112014010391 A2 BR 112014010391A2 BR 112014010391 A BR112014010391 A BR 112014010391A BR 112014010391 A BR112014010391 A BR 112014010391A BR 112014010391 A2 BR112014010391 A2 BR 112014010391A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
kit
compound
producing
treatment
Prior art date
Application number
BR112014010391A
Other languages
English (en)
Portuguese (pt)
Inventor
Fred Ortwine Daniel
John Crawford James
B Young Wendy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014010391A2 publication Critical patent/BR112014010391A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
BR112014010391A 2011-11-03 2012-11-02 composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica BR112014010391A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555396P 2011-11-03 2011-11-03
PCT/US2012/063171 WO2013067260A1 (en) 2011-11-03 2012-11-02 Bicyclic piperazine compounds

Publications (1)

Publication Number Publication Date
BR112014010391A2 true BR112014010391A2 (pt) 2017-04-18

Family

ID=47279001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010391A BR112014010391A2 (pt) 2011-11-03 2012-11-02 composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica

Country Status (12)

Country Link
US (1) US8722676B2 (zh)
EP (1) EP2773640B1 (zh)
JP (1) JP5808869B2 (zh)
KR (1) KR20140096100A (zh)
CN (1) CN104105697B (zh)
BR (1) BR112014010391A2 (zh)
CA (1) CA2852964A1 (zh)
ES (1) ES2552514T3 (zh)
HK (1) HK1201268A1 (zh)
MX (1) MX2014005285A (zh)
RU (1) RU2628616C2 (zh)
WO (1) WO2013067260A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5832664B2 (ja) * 2011-12-09 2015-12-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
EP2813504A1 (en) * 2013-06-14 2014-12-17 Institut Quimic De Sarriá Cets, Fundació Privada 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof
KR101815360B1 (ko) 2013-07-03 2018-01-04 에프. 호프만-라 로슈 아게 헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
EP3077384B1 (en) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
CN105722834B (zh) 2013-12-13 2017-12-22 豪夫迈·罗氏有限公司 酪氨酸蛋白激酶抑制剂
CA2942204A1 (en) 2014-03-12 2015-09-17 Novartis Ag Combination comprising a btk inhibitor and an akt inhibitor
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
WO2015177367A1 (en) 2014-05-23 2015-11-26 Active Biotech Ab Novel compounds useful as s100-inhibitors
CN106922146B (zh) 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
JP6368043B2 (ja) * 2014-10-27 2018-08-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式ラクタム化合物の製造法
ES2907988T3 (es) * 2015-03-10 2022-04-27 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
CN104744463A (zh) * 2015-03-31 2015-07-01 山东友帮生化科技有限公司 6-氯-8-溴咪唑并[1,2-a]吡啶的合成方法
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2019532998A (ja) 2016-11-08 2019-11-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｐｆｋｆｂ阻害剤としての置換キノキサリン誘導体
EP3548484A1 (en) * 2016-12-02 2019-10-09 H. Hoffnabb-La Roche Ag Bicyclic amide compounds and methods of use thereof
TWI766176B (zh) * 2016-12-15 2022-06-01 瑞士商赫孚孟拉羅股份公司 製備btk抑制劑之方法
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
CN109206435B (zh) * 2017-06-29 2020-09-08 中国医药研究开发中心有限公司 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
TWI805595B (zh) 2017-07-14 2023-06-21 瑞士商赫孚孟拉羅股份公司 二環酮化合物及其使用方法
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
CN110256446B (zh) * 2018-08-01 2021-12-14 上海海雁医药科技有限公司 苯并杂环取代的环戊二烯并[4,5]吡咯并吡嗪-1-酮衍生物及其应用
CN113939292A (zh) 2019-02-25 2022-01-14 广州麓鹏制药有限公司 Btk及其突变体的抑制剂
US20220363689A1 (en) 2019-10-05 2022-11-17 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
EP4107154A4 (en) 2020-02-20 2024-02-28 Hutchison Medipharma Ltd HETEROARYL HETEROCYCLIC COMPOUNDS AND THEIR USES
CN115461343A (zh) * 2020-04-30 2022-12-09 百济神州(北京)生物科技有限公司 Ptotac btk降解剂的制备方法
CN115715291A (zh) * 2020-06-18 2023-02-24 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法
IL301275A (en) * 2020-09-21 2023-05-01 Hutchison Medipharma Ltd Heterocyclic heteroaryl compounds and their uses
US20230382900A1 (en) 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
US20240058457A1 (en) 2020-12-20 2024-02-22 Newave Pharmaceutical Inc. Btk degrader
WO2023143491A1 (zh) * 2022-01-28 2023-08-03 和记黄埔医药（上海）有限公司 7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
DE4224133A1 (de) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CA2453113A1 (en) 2001-07-12 2003-01-23 Avecia Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
KR101357524B1 (ko) 2005-03-10 2014-02-03 질레드 코네티컷 인코포레이티드 특정 치환된 아미드, 그의 제조 방법, 및 사용 방법
AU2006302415B2 (en) 2005-10-07 2012-09-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
KR101315610B1 (ko) * 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN101952283B (zh) * 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AU2009244291B2 (en) 2008-05-06 2014-02-13 Genentech, Inc. Substituted amides, method of making, and use as Btk inhibitors
EP2297142B1 (en) * 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
RU2507202C2 (ru) 2008-07-02 2014-02-20 Ф.Хоффманн-Ля Рош Аг Новые фенилпиразиноны в качестве ингибиторов киназы
JP5318952B2 (ja) 2008-07-15 2013-10-16 エフ．ホフマン−ラ ロシュ アーゲー 新規なフェニル−イミダゾピリジン類及びピリダジン類
KR101358532B1 (ko) * 2008-07-18 2014-02-05 에프. 호프만-라 로슈 아게 신규한 페닐이미다조피라진
JP2011529073A (ja) * 2008-07-24 2011-12-01 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ調節因子として有用な縮合ヘテロ環化合物
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
WO2010068810A2 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
WO2010126960A1 (en) * 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
DK2473049T3 (en) * 2009-09-04 2019-04-01 Biogen Ma Inc INHIBITORS OF BRUTON'S TYROSINKINASE
US9562056B2 (en) * 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
CA3034600C (en) 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US9249123B2 (en) 2010-09-01 2016-02-02 Genentech, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
JP5842004B2 (ja) 2010-09-01 2016-01-13 ジーアイリード コネチカット インコーポレーテッドＧｉｌｅａｄ Ｃｏｎｎｅｃｔｉｃｕｔ，Ｉｎｃ． ピリダジノン、その製造方法及びその使用方法
KR101585753B1 (ko) 2011-05-17 2016-01-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
PE20140865A1 (es) 2011-08-17 2014-07-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
WO2013067260A1 (en) 2013-05-10
EP2773640B1 (en) 2015-08-19
MX2014005285A (es) 2014-05-30
US8722676B2 (en) 2014-05-13
US20130116262A1 (en) 2013-05-09
EP2773640A1 (en) 2014-09-10
HK1201268A1 (zh) 2015-08-28
JP2014532715A (ja) 2014-12-08
CN104105697B (zh) 2016-11-09
ES2552514T3 (es) 2015-11-30
RU2014121073A (ru) 2015-12-10
KR20140096100A (ko) 2014-08-04
CA2852964A1 (en) 2013-05-10
RU2628616C2 (ru) 2017-08-21
CN104105697A (zh) 2014-10-15
JP5808869B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
BR112014010391A2 (pt) composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014010439A2 (pt) compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
BR112013014599A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênca estável, e, kit
BR112014026815A2 (pt) composição cosmética, processo cosmético e uso de uma composição cosmética
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
BR112012029227A2 (pt) processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto
BR112013025814A2 (pt) composição e processo
BR112013030832A2 (pt) processo para tratar as fibras queratínicas e uso de uma composição
BR112013007276A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112014012243A2 (pt) processo de preparação de compostos
BR112013006232A2 (pt) processo de tratamento cosmético, composto e composição cosmética
BR112012021066A2 (pt) processo de preparação de uma composição, composição e aplicação da composição
BR112014026565A2 (pt) formulação, uso de uma formulação, e, processo para produzir uma formulação
BR112014010997A2 (pt) processo para o preparo de ß-glicosídeos de c-arila
BR112013015891A2 (pt) uso de uma combinação, método de tratamento de um plasma e uso de uma combinação
BR112014015525A2 (pt) processo de fabricação de uma benzoxazinona, uso de uma benzoxazinona e benzoxazinona
BR112013022930A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, processo para produzir uma composição farmacêutica
BR112014015526A2 (pt) processo de fabricação de triazinona-benzoxazinonas e uso de uma amino-benzoxazinona
BR112014012759A8 (pt) composto, composição e método para tratamento
BR112012022037A2 (pt) composição cosmética, processo de tratamento cosmético, uso de uma composição cosmética e uso de uma combinação
BR112013006857A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2538 DE 27-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.